Phil Wells1, W Frank Peacock2, Gregory J Fermann3, Craig I Coleman4, Li Wang5, Onur Baser6,7, Jeff Schein8, Concetta Crivera8. 1. University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada. 2. Baylor College of Medicine, Houston, TX, USA. 3. University of Cincinnati, Cincinnati, OH, USA. 4. University of Connecticut, Storrs, CT, USA. 5. STATinMED Research, Analytic Research, Plano, TX, USA. lwang@statinmed.com. 6. Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 7. STATinMED Research, Health Economics & Outcomes Research, New York, NY, USA. 8. Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
Abstract
INTRODUCTION: Various risk stratification methods exist for patients with pulmonary embolism (PE). We used the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health Administration (VHA) PE population. MATERIALS AND METHODS: Adult patients with ≥ 1 inpatient PE diagnosis (index date = discharge date) from October 2011-June 2015 as well as continuous enrollment for ≥ 12 months pre- and 3 months post-index date were included. We defined a sPESI score of 0 as low-risk (LRPE) and all others as high-risk (HRPE). Hospital-acquired complications (HACs) during the index hospitalization, 90-day follow-up PE-related outcomes, and health care utilization and costs were compared between HRPE and LRPE patients. RESULTS: Of 6746 PE patients, 95.4% were men, 67.7% were white, and 22.0% were African American; LRPE occurred in 28.4% and HRPE in 71.6%. Relative to HRPE patients, LRPE patients had lower Charlson Comorbidity Index scores (1.0 vs. 3.4, p < 0.0001) and other baseline comorbidities, fewer HACs (11.4% vs. 20.0%, p < 0.0001), less bacterial pneumonia (10.6% vs. 22.3%, p < 0.0001), and shorter average inpatient lengths of stay (8.8 vs. 11.2 days, p < 0.0001) during the index hospitalization. During follow-up, LRPE patients had fewer PE-related outcomes of recurrent venous thromboembolism (4.4% vs. 6.0%, p = 0.0077), major bleeding (1.2% vs. 1.9%, p = 0.0382), and death (3.7% vs. 16.2%, p < 0.0001). LRPE patients had fewer inpatient but higher outpatient visits per patient, and lower total health care costs ($12,021 vs. $16,911, p < 0.0001) than HRPE patients. CONCLUSIONS: Using the sPESI score identifies a PE cohort with a lower clinical and economic burden.
INTRODUCTION: Various risk stratification methods exist for patients with pulmonary embolism (PE). We used the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health Administration (VHA) PE population. MATERIALS AND METHODS: Adult patients with ≥ 1 inpatient PE diagnosis (index date = discharge date) from October 2011-June 2015 as well as continuous enrollment for ≥ 12 months pre- and 3 months post-index date were included. We defined a sPESI score of 0 as low-risk (LRPE) and all others as high-risk (HRPE). Hospital-acquired complications (HACs) during the index hospitalization, 90-day follow-up PE-related outcomes, and health care utilization and costs were compared between HRPE and LRPE patients. RESULTS: Of 6746 PE patients, 95.4% were men, 67.7% were white, and 22.0% were African American; LRPE occurred in 28.4% and HRPE in 71.6%. Relative to HRPE patients, LRPE patients had lower Charlson Comorbidity Index scores (1.0 vs. 3.4, p < 0.0001) and other baseline comorbidities, fewer HACs (11.4% vs. 20.0%, p < 0.0001), less bacterial pneumonia (10.6% vs. 22.3%, p < 0.0001), and shorter average inpatient lengths of stay (8.8 vs. 11.2 days, p < 0.0001) during the index hospitalization. During follow-up, LRPE patients had fewer PE-related outcomes of recurrent venous thromboembolism (4.4% vs. 6.0%, p = 0.0077), major bleeding (1.2% vs. 1.9%, p = 0.0382), and death (3.7% vs. 16.2%, p < 0.0001). LRPE patients had fewer inpatient but higher outpatient visits per patient, and lower total health care costs ($12,021 vs. $16,911, p < 0.0001) than HRPE patients. CONCLUSIONS: Using the sPESI score identifies a PE cohort with a lower clinical and economic burden.
Entities:
Keywords:
Cost of illness; Pulmonary embolism; Trauma Severity Index; Veterans Health Administration
Authors: F Dentali; N Riva; S Turato; S Grazioli; A Squizzato; L Steidl; L Guasti; A M Grandi; W Ageno Journal: J Thromb Haemost Date: 2013-12 Impact factor: 5.824
Authors: Andrew Cunningham; C Michael Stein; Cecilia P Chung; James R Daugherty; Walter E Smalley; Wayne A Ray Journal: Pharmacoepidemiol Drug Saf Date: 2011-03-08 Impact factor: 2.890
Authors: David Jiménez; Drahomir Aujesky; Lisa Moores; Vicente Gómez; José Luis Lobo; Fernando Uresandi; Remedios Otero; Manuel Monreal; Alfonso Muriel; Roger D Yusen Journal: Arch Intern Med Date: 2010-08-09
Authors: D Sorbello; H M Dewey; L Churilov; A G Thrift; J M Collier; G Donnan; J Bernhardt Journal: Cerebrovasc Dis Date: 2009-07-30 Impact factor: 2.762
Authors: Siavash Piran; Grégoire Le Gal; Philip S Wells; Esteban Gandara; Marc Righini; Marc A Rodger; Marc Carrier Journal: Thromb Res Date: 2013-08-28 Impact factor: 3.944
Authors: Jean-Pierre Iskandar; Essa Hariri; Christopher Kanaan; Nicholas Kassis; Hayaan Kamran; Denise Sese; Colin Wright; Mark Marinescu; Scott J Cameron Journal: J Thromb Thrombolysis Date: 2021-09-29 Impact factor: 2.300
Authors: David Jiménez; Carmen Rodríguez; Beatriz Pintado; Andrea Pérez; Luis Jara-Palomares; Raquel López-Reyes; Pedro Ruiz-Artacho; Alberto García-Ortega; Behnood Bikdeli; José Luis Lobo Journal: Front Cardiovasc Med Date: 2022-04-12
Authors: Pierre-Marie Roy; Andrea Penaloza; Olivier Hugli; Frederikus A Klok; Armelle Arnoux; Antoine Elias; Francis Couturaud; Luc-Marie Joly; Raphaëlle Lopez; Laura M Faber; Marie Daoud-Elias; Benjamin Planquette; Jérôme Bokobza; Damien Viglino; Jeannot Schmidt; Henry Juchet; Isabelle Mahe; Frits Mulder; Magali Bartiaux; Rosen Cren; Thomas Moumneh; Isabelle Quere; Nicolas Falvo; Karine Montaclair; Delphine Douillet; Charlotte Steinier; Stephan V Hendriks; Ygal Benhamou; Tali-Anne Szwebel; Gilles Pernod; Nicolas Dublanchet; François-Xavier Lapebie; Nicolas Javaud; Alexandre Ghuysen; Mustapha Sebbane; Gilles Chatellier; Guy Meyer; David Jimenez; Menno V Huisman; Olivier Sanchez Journal: Eur Heart J Date: 2021-08-31 Impact factor: 29.983